Related Experiment Video
Updated: Jun 6, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
Potential effects of beta-blockers in HFpEF
Wojciech Tokarczyk1, Szymon Urban2, Patryk Patrzałek3
1Institute of Heart Diseases, University Hospital in Wrocław, Wrocław, Poland. wojciech.tokarczyk98@gmail.com.
Heart Failure Reviews
|December 3, 2024
Summary
Beta-blockers offer uncertain benefits for heart failure with preserved ejection fraction (HFpEF). More research is needed to clarify their role in HFpEF management and improve patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with preserved ejection fraction (HFpEF) presents significant challenges, including reduced quality of life and increased mortality.
- Current treatment strategies for HFpEF are limited, with unclear guidance on beta-blocker use.
Purpose of the Study:
- To review the current evidence on the use of beta-blockers in patients with HFpEF.
- To identify gaps in knowledge and areas for future research regarding beta-blocker efficacy in HFpEF.
Main Methods:
- Literature review of existing studies on beta-blocker use in HFpEF.
- Analysis of potential benefits and risks, including effects on sympathetic activity, chronotropic competence, and exercise tolerance.
Main Results:
- Beta-blockers may reduce sympathetic activity but can worsen chronotropic incompetence and decrease exercise tolerance in HFpEF.
- Evidence on clinical endpoints, including mortality and hospitalizations, remains inconclusive.
- Potential benefits may differ across ejection fraction subgroups (e.g., HFmrEF vs. HFpEF).
Conclusions:
- The role of beta-blockers in HFpEF management is not well-defined.
- Large-scale randomized clinical trials are essential to establish clear treatment guidelines.
- Further research is needed to optimize therapeutic protocols for HFpEF.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
529
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
529
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:28Antihypertensive Drugs: Types of β-Blockers
582
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
582
01:22Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K